Savient sales and marketing update

Savient said in its 1Q13 earnings that it raised the wholesale acquisition cost of gout drug Krystexxa pegloticase in the U.S. to $3,850 for an 8 mg/mL dose given every two weeks. The price, which went into effect Jan. 16, is a 67% increase to the $2,300 list price at the time of the U.S. launch in December 2010. The company said it increased the price by about 29% to $2,962 per 8 mg/mL dose last year, followed by an additional 30% increase in January (see BioCentury, Dec. 6, 2010). ...